Stage IV colon cancer patient receiving immunotherapy



> *Unfortunately, I never had any symptoms of colon cancer. Perhaps if I had, I would have gotten a colonoscopy at an earlier age. After awakening from the sedation and barely coherent, my doctor told me there was a 7 cm mass in my cecum.*

Patient history:

- 55-year-old woman presented with right-sided colonic adenocarcinoma and omental and focal liver metastases
- No evidence of disease after neoadjuvant chemotherapy and surgical resection of primary tumor and metastatic foci
- Despite normal CEA levels, recurrence was detected in the abdominal wall and lymph node after completion of adjuvant chemotherapy

How Signatera was incorporated:

- Serial Signatera ctDNA results were used as alternative indicators of tumor burden
- Signatera ctDNA testing provided an early indication of tumor response to immune-checkpoint inhibition

DIAGNOSIS
Right-sided colonic adenocarcinoma with involvement of omentum and liver

PATHOLOGY
- Moderately differentiated cecal adenocarcinoma
- 0/23 lymph nodes positive
- One omental focus and one focus in the liver with clear margin
- NED after surgery

TUMOR MOLECULAR PROFILING
- TMB: 15.4 mut/MB
- pMMR/MSS
- PD-L1 CPS score: 26

GI recurrence and lymph node metastasis

Lymph node progression from 5 mm to 12 mm

Lymph node resolved radiographically after 2 cycles



DECEMBER 2017

The report read 'hepatic metastatic tumors in both lobes.' Things went black. My brother, mother, and sister all had cancer, two of whom had passed because of it. I knew what it meant.

FEBRUARY 2020

In 2020, right before the pandemic hit, a recurrence was discovered via a CT scan.

MARCH 2020

Before my surgery, I called Natera to inquire about Signatera and told my oncologist about it. I also asked the surgeon to send a tissue sample of my tumor for the test.

Signatera ctDNA analysis

MAY 2020

We knew the cancer was growing, and now it showed up in a lymph node by my heart. We needed to act quickly.

JULY 2020

On a Sunday morning at 8 am, my oncologist called to tell me the Signatera liquid biopsy was zero, zilch, nada, nothing.

On the PET scan, anything that had been visible prior was now completely gone.

CEA=carcinoembryonic antigen; **CPS**=combined positive score; **ctDNA**=circulating tumor DNA; **NED**=no evidence of disease; **MSS**=microsatellite stable; **pMMR**=proficient mismatch repair; **MTM**=mean tumor molecules; **TMB**=tumor mutational burden

This case study was presented at the Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting.

Schneider CJ, Krainock M, Malhotra M, et al. ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy. Poster presented at SITC 2020 Virtual Meeting; November 10-15, 2020. Poster #26.

The Takeaway

- ctDNA is a dynamic biomarker for monitoring tumor response to immune checkpoint inhibitor treatment, when used in conjunction with radiographic imaging.
- ctDNA can be used as a serologic surrogate to assess systemic disease burden and may outperform standard biomarkers such as CEA.

Value of Signatera



- Signatera is a personalized, tumor-informed assay for ultrasensitive, real-time detection of molecular residual disease.
- Rapid ctDNA clearance correlated with radiographic resolution of metastatic disease provides confidence that Signatera can be used to identify early response during immunotherapy response monitoring.

Learn more at nateraoncology.com

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | oncology.natera.com | 1.650.489.9050 | Fax 1.650.412.1962

natera™